Prostate Cancer
Research

Volume 7 Number 9
September 2019

Home > Disciplines > Publications > Prostate Cancer Research > Volume 7, Year 2019 > Number 9, September

CONTENTS

▼

DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
FOLLOW-UP, QUALITY OF LIFE
PROGNOSIS
TREATMENT

DIAGNOSIS

▲

Arabi A, Deebaja M, Yaguchi G, Pantelic M, Williamson S, Gupta N, Park H, Peabody J, Menon M, Dabaja A, Alanee S.
Systematic biopsy does not contribute to disease upgrading in patients undergoing targeted biopsy for PI-RADS 5 lesions identified on magnetic resonance imaging in the course of active surveillance for prostate cancer.
Urology. 2019 Aug 31. pii: S0090-4295(19)30789-7. doi: 10.1016/j.urology.2019.08.035. [Epub ahead of print]
Source . Similar articles

Asokendaran ME, Meyrick DP, Skelly LA, Lenzo NP, Henderson A.
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer.
World J Nucl Med. 2019 Jul-Sep;18(3):232-237. doi: 10.4103/wjnm.WJNM_59_18. Epub 2019 Aug 9.
Source . Similar articles

Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF.
Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer.
Prostate Cancer Prostatic Dis. 2019 Sep 9. doi: 10.1038/s41391-019-0171-0. [Epub ahead of print]
Source . Similar articles

Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Briganti A, Schiavina R, Brunocilla E, Castellucci P, Fanti S.
Prediction nomogram for ⁶⁸Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Sep 6. doi: 10.1007/s00259-019-04505-2. [Epub ahead of print]
Source . Similar articles

Choi SY, Lim B, Kyung YS, Kim Y, Kim BM, Jeon BH, Park JC, Sohn YW, Lee JH, Uh JH, Jang S, Kim CS.
Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance.
In Vivo. 2019 Sep-Oct;33(5):1615-1620. doi: 10.21873/invivo.11645. Published online 2019 Sep 3.
Source . Similar articles

Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, Hermanns T, Burger IA.
⁶⁸Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Sep 14. doi: 10.1007/s00259-019-04511-4. [Epub ahead of print]
Source . Similar articles

Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
Whole-Body Integrated [⁶⁸Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
Mol Imaging Biol. 2019 Sep 3. doi: 10.1007/s11307-019-01424-4. [Epub ahead of print]
Source . Similar articles

Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG.
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00176. Epub 2019 Sep 9.
Source . Similar articles

Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom HAM, van Oosterom MN, van Leeuwen FWB, van der Poel HG.
Prostate-specific membrane antigen positron emission tomography/computed tomography combined with sentinel node biopsy for primary lymph node staging in prostate cancer.
J Nucl Med. 2019 Sep 27. pii: jnumed.119.232199. doi: 10.2967/jnumed.119.232199. [Epub ahead of print]
Source . Similar articles

Jayadevan R, Felker ER, Kwan L, Barsa DE, Zhang H, Sisk AE, Delfin M, Marks LS.
Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
JAMA Netw Open. 2019 Sep 4;2(9):e1911019. doi: 10.1001/jamanetworkopen.2019.11019.
Source . Similar articles

Knaapila J, Jambor I, Perez IM, Ettala O, Taimen P, Verho J, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ.
Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
Eur Urol Oncol. 2019 Sep 6. pii: S2588-9311(19)30134-8. doi: 10.1016/j.euo.2019.08.008. [Epub ahead of print]
Source . Similar articles

Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E.
Head- to head Comparison of ⁶⁸Ga-PSMA-11 with ¹⁸F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard.
J Nucl Med. 2019 Sep 27. pii: jnumed.119.234187. doi: 10.2967/jnumed.119.234187. [Epub ahead of print]
Source . Similar articles

Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS, Müller J, Rupp NJ, Rüschoff JH, Eberli D, Donati OF.
Diagnostic Accuracy of Multiparametric MRI versus ⁶⁸Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
Radiology. 2019 Sep 10:190687. doi: 10.1148/radiol.2019190687. [Epub ahead of print]
Source . Similar articles

Natarajan A, Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, Shah S, Puranik A, Rangarajan V.
Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
World J Nucl Med. 2019 Jul-Sep;18(3):244-250. doi: 10.4103/wjnm.WJNM_47_18.
Source . Similar articles

Rourke E, Sunnapwar A, Mais D, Kukkar V, DiGiovanni J, Kaushik D, Liss MA.
Inflammation appears as high Prostate Imaging-Reporting and Data System scores on prostate magnetic resonance imaging (MRI) leading to false positive MRI fusion biopsy.
Investig Clin Urol. 2019 Sep;60(5):388-395. doi: 10.4111/icu.2019.60.5.388. Epub 2019 Jul 30.
Source . Similar articles

Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
PSMA SPECT/CT with ^99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
Ann Nucl Med. 2019 Sep 9. doi: 10.1007/s12149-019-01400-6. [Epub ahead of print]
Source . Similar articles

EPIDEMIOLOGY, RISK FACTORS, PREVENTION

▲

Khan S, Thakkar S, Drake B.
Smoking history, intensity, and duration and risk of prostate cancer recurrence among men with prostate cancer who received definitive treatment.
Ann Epidemiol. 2019 Sep 6. pii: S1047-2797(19)30334-5. doi: 10.1016/j.annepidem.2019.08.011. [Epub ahead of print]
Source . Similar articles

*

Pal M, Hodge AM, Papa N, MacInnis RJ, Bassett JK, Bolton D, Davis ID, Millar J, English DR, Hopper JL, Severi G, Southey MC, Milne RL, Giles GG.
Body size and dietary risk factors for aggressive prostate cancer: a case-control study.
Cancer Causes Control. 2019 Sep 24. doi: 10.1007/s10552-019-01234-7. [Epub ahead of print]
Source . Similar articles

FOLLOW-UP, QUALITY OF LIFE

▲

Schifano N, Capogrosso P, Pozzi E, Ventimiglia E, Cazzaniga W, Matloob R, Gandaglia G, Dehò F, Briganti A, Montorsi F, Salonia A.
Impact of time from diagnosis to treatment on erectile function outcomes after radical prostatectomy.
Andrology. 2019 Sep 3. doi: 10.1111/andr.12699. [Epub ahead of print] -
Source . Similar articles

PROGNOSIS

▲

Branger N, Pignot G, Lannes F, Koskas Y, Toledano H, Thomassin-Piana J, Giusiano S, Alessandrini M, Rossi D, Walz J, Bastide C.
Comparison between Zumsteg classification and Briganti nomogram for the risk of lymph-node invasion before radical prostatectomy.
World J Urol. 2019 Sep 27. doi: 10.1007/s00345-019-02965-7. [Epub ahead of print]
Source . Similar articles

Kim SJ, Ryu JH, Yang SO, Lee JK, Jung TY, Kim YB.
Does the Time Interval from Biopsy to Radical Prostatectomy Affect the Postoperative Oncologic Outcomes in Korean Men?
J Korean Med Sci. 2019 Sep 30;34(37):e234. doi: 10.3346/jkms.2019.34.e234.
Source . Similar articles

Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M.
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30251-4. doi: 10.1016/j.clgc.2019.08.002. [Epub ahead of print]
Source . Similar articles

*

Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Tanaka N, Takeda T, Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M.
Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
World J Urol. 2019 Sep 26. doi: 10.1007/s00345-019-02970-w. [Epub ahead of print]
Source . Similar articles

Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.
Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.
BMC Urol. 2019 Sep 9;19(1):84. doi: 10.1186/s12894-019-0515-z.
Source . Similar articles

Preisser F, Coxilha G, Heinze A, Oh S, Chun FK, Sauter G, Pompe RS, Huland H, Graefen M, Tilki D.
Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer.
Prostate. 2019 Sep 25. doi: 10.1002/pros.23908. [Epub ahead of print] -
Source . Similar articles

TREATMENT

▲

Aparicio A, Thall P, Logothetis C.
Radiotherapy for metastatic prostate cancer.
Lancet. 2019 Sep 7;394(10201):829-830. doi: 10.1016/S0140-6736(19)31783-0.
Source . Similar articles
Comment on: Parker CC, James ND, et al.,Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21. Source . Similar articles

Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K, Haustermans K, Devos G, De Meerleer G.
Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
Eur Urol Oncol. 2019 Sep 23. pii: S2588-9311(19)30138-5. doi: 10.1016/j.euo.2019.08.012. [Epub ahead of print]
Source . Similar articles

Gouda MA.
Radiotherapy for metastatic prostate cancer.
Lancet. 2019 Sep 7;394(10201):829. doi: 10.1016/S0140-6736(19)31782-9.
Source . Similar articles
Comment on: Parker CC, James ND, et al.,Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21. Source . Similar articles

Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.
External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
Int Urol Nephrol. 2019 Sep 21. doi: 10.1007/s11255-019-02284-1. [Epub ahead of print]
Source . Similar articles

Marzec J, Becker J, Paulsen F, Wegener D, Olthof SC, Pfannenberg C, Schwenck J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.
⁶⁸Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery.
Acta Oncol. 2019 Sep 27:1-8. doi: 10.1080/0284186X.2019.1669816. [Epub ahead of print]
Source . Similar articles

Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D'agostino G, Corradini S, Alongi F, Scorsetti M.
Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
Strahlenther Onkol. 2019 Sep 26. doi: 10.1007/s00066-019-01523-9. [Epub ahead of print]
Source . Similar articles

Parker CC, James ND, Brawley CD, Clarke NW, Parmar MKB.
Radiotherapy for metastatic prostate cancer-Authors' reply.
Lancet. 2019 Sep 7;394(10201):830. doi: 10.1016/S0140-6736(19)31829-X.
Source . Similar articles
Comment on: (1) Aparicio A et al.,Radiotherapy for metastatic prostate cancer. Lancet. 2019 Sep 7;394(10201):829-830. doi: 10.1016/S0140-6736(19)31783-0. Source . Similar articles (2) Gouda MA.,Radiotherapy for metastatic prostate cancer. Lancet. 2019 Sep 7;394(10201):829. doi: 10.1016/S0140-6736(19)31782-9. Source . Similar articles

Parker CC, James ND, et al.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.
Source . Similar articles

bottom

▲